Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) — The “Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATDs in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.
Key Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Key Report Strengths
- 11 Year Forecast
- 6MM Coverage
Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Key Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Topics Covered:
1 Key Insights
2 Executive Summary of Alpha Antitrypsin Deficiency
3 SWOT Analysis for Alpha Antitrypsin Deficiency
4 Patient Share of Alpha Antitrypsin Deficiency at a Glance
5 Alpha Antitrypsin Deficiency Market Overview at a Glance
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency
9 Treatment
10 Treatment Algorithm
11 Unmet Needs
12 Organizations contributing toward Alpha Antitrypsin Deficiency
13 Case Reports
14 Marketed Drugs
15 Emerging Therapies
16 Other Promising Candidates
17 Alpha Antitrypsin Deficiency: 6 Major Market Analysis
18 Alpha Antitrypsin Deficiency: Country-Wise Market Analysis
19 Grifols Initiatives towards Alpha Antitrypsin deficiency
20 US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)
21 Market Drivers
22 Market Barriers
23 Access and Reimbursement Overview of Alpha Antitrypsin Deficiency
Companies Mentioned
- Grifols
- Kamada
- Shire
- CSL Behring
- LFB Biotechnologies
- Alnylam Pharmaceuticals
- Arrow Head Pharmaceuticals
- Vertex Pharmaceuticals
- Mereo Biopharma
- Dicerna Pharmaceuticals
- Inhibrx
- Vertex Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r7n05q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
